Pharmaceuticals

[New] The global outsourcing services market for drug and medical device development is expected to grow from 130.5 billion pounds in 2020 to 205.6 billion pounds by 2025 with a compound annual growth rate of 9.5% for the period of 2020-2025.
[New] China is by far the biggest emerging market for pharmaceuticals, with growth expected to reach USD $175 billion by 2022 as healthcare total expenditures grow at double digit rates.
[New] As pharmaceutical giants become aware of the potential AI contains, the coming years will see a radical shift in how companies big and small work and strategise.
Last year, the Philippines signed more than $18 billion worth of BRI agreements including Chinese grants that could help with the government's ongoing war against drugs.
Global pharmaceutical sales are predicted to reach USD 1567.80 billion by 2023 and based on the launch of new technologies and the approval of the first cell and gene therapies the estimate in prescription drug sales in 2024 is $1.18trn.
By 2023, North America is expected to retain its leading position in the global pharmaceuticals market with a market share of 45%.
The pharmaceutical industry's spending on AI in drug discovery is expected to grow from $465 million in 2020 to $2 billion by 2026.
ATB market is expected to increase of 33% up to 2022, covering 67% of the total Italian market, mostly due to adalimumab and etanercept (44%) biosimilars uptake.
Even if the Trump administration is currently unlikely to support an international effort to distribute drugs, other advanced countries acting together could create the political pressure to bring the United States in.
The artificial intelligence for drug discovery and development market was valued at $520 million in 2019 and is projected to reach $4,815 million by 2027, registering a CAGR of 31.6% from 2020 to 2027.
Just four weeks of the current global sales of brand name HIV drugs ($2bn) could treat 95% of people living with HIV for a whole year.
2021 could be a strong growth year, after a Coronavirus vaccine is found and pent up demand produces a wave of new and existing drug and rehabilitation patients.
The global Cardiology Surgery, Devices and Drugs market Growth is anticipated to rise at a considerable rate during the forecast period, between 2020 and 2025.
Over the past decade, organoid research has raised hopes, particularly in terms of personalized medicine and improved screening for new drugs.
Swiss pharma giant Novartis has brought a gene therapy to market, while an oral drug from Roche could soon gain approval in the U.S. as well.
Projected increases in health plan costs for 2020 are similar to 2019, but increases for high-cost specialty prescription drugs will continue to skyrocket.
The worldwide market for drug, Glucagon is expected to grow at a CAGR of roughly 6.2% over the next five years, will reach 620 million USUSD in 2024, from 430 million USUSD in 2019.
Over one million people are using open banking technology in the UK: 2020 will be the year when adoption of open banking financial services really takes off.
When partnered with the greater cloud access to SWIFT, and new API opportunities from Open Banking, adoption of digital solutions are likely to accelerate in the new post-COVID - 19 world.
Open Banking will change the structure of banking as new operational models arise through open innovation and platform-based business models.
Inspired by Open Banking, open data across the whole economy could ease frictions in the financial system, in particular to help close the £22bn funding gap for small and medium-sized enterprises (SMEs) across the UK.
The movement toward open banking and open APIs will only increase the speed of change as fintech business models and technologies allow them to align with new opportunities very quickly.
The UK's efforts to implement Open Banking have had zero positive impact on innovation in the banking sector.

See full forecast

Last updated: 15 September 2020